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| BACKG ROU N D
Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of death according to the 2018 global cancer statistics. 1 CRC has the third highest incidence and the fifth highest fatality rate in China. 2 TNM staging is an important prognostic factor for patients with CRC. However, patients with metastatic colorectal cancer (mCRC) in the same TNM stage have different survival times. Therefore, there is an urgent need for new clinical predictors to predict chemotherapy efficacy and survival time in patients with mCRC.
Differences in survival time and chemotherapy responses in cancer patients occur due to a host of factors, including systemic inflammation and nutritional status. Previous studies have shown that proinflammatory chemokines and cytokines in the tumor microenvironment promote the occurrence, development, and metastasis of tumors, destroy human immunity, and reduce the therapeutic response of tumors to cytotoxic drugs, ultimately affecting survival. [3] [4] [5] [6] At the same time, malnutrition is an important issue in cancer patients and can lead to a series of clinical consequences, such as cachexia, a lower response to treatment, and shorter survival. 7 Among several systemic inflammatory and nutritional status biomarkers, fibrinogen, albumin, globulin, the neutrophil-to-lymphocyte ratio (NLR), the albumin-toglobulin ratio (AGR), the lymphocyte-to-monocyte ratio (LMR), the platelet-to-lymphocyte ratio (PLR), and the fibrinogen-to-albumin ratio (FAR) have been used as prognostic indicators for different types of cancer. Some of these factors are also predictors of therapeutic efficacy in cancer patients receiving cytotoxic drug therapy.
These prognostic factors have also been used to predict the prognosis of CRC patients. [8] [9] [10] A relationship between the pretreatment AGR, NLR, LMR, and PLR and the chemotherapy response in patients with CRC has been reported by many studies. [10] [11] [12] [13] [14] In addition, the prealbumin produced by the liver has a shorter half-life and a lower plasma level than albumin, allowing even a slight change in malnutrition to be seen in a short amount of time, making it a more effective biomarker of malnutrition and inflammatory stress than albumin. 15, 16 In fact, recent studies have shown that the fibrinogen-to-prealbumin ratio (FPR) could be a useful CRC diagnostic and prognostic biomarker. 17, 18 However, relatively little research has been performed on the FAR, FPR, and prealbumin-to-globulin ratio (PGR) in patients with mCRC.
The objective of this study was to evaluate whether the pretreatment FAR, FPR, PGR, and other potential prognostic factors could be used as markers of chemotherapy response and prognostic factors for progression-free survival (PFS) in patients with mCRC. A total of seven potential prognostic factors were used in this study, including AGR, FAR, PGR, FPR, LMR, NLR, and PLR.
| ME THODS

| Patient selection
In this retrospective study, 71 patients diagnosed with mCRC at the Cancer Hospital of China Medical University (Liaoning, China) were collected and followed up from June 2015 to February 2019. All patients met the following enrollment criteria: (a) biopsy-confirmed CRC; (b) an unresectable metastatic lesion diagnosed by imaging; (c) no intestinal obstructions before treatment and no other complications preventing patients from meeting the requirements for chemotherapy; (d) at least two cycles of chemotherapy were completed; (e) the required blood tests were completed within 1-2 weeks before initial first-line chemotherapy; (f) an Eastern Cooperative Oncology Group performance status (PS) score of 0-2; and (g) patients who had preexisting liver disease, chronic renal failure, severe acute or chronic inflammatory disease, or patients who received oral anticoagulation therapy were excluded from this study. All enrolled patients volunteered to participate in this study. This study was approved by the Cancer Hospital of China Medical University Ethics Committee.
| Patient follow-up
All patients were followed up. After completing the required chemotherapy cycle, all patients were evaluated every 8 weeks until disease progression was detected. The median follow-up time in this study was 200 days (range, 56-815 days).
| Clinical data collection
We collected information on patient characteristics before chemotherapy from the hospital records; the location of the tumor in the intestine by colonoscopy and the number of metastatic organs were determined by a computed tomography scan, magnetic resonance imaging, or other imaging examinations. The RAS/BRAF genotype was determined by genetic testing within 1-2 weeks before chemotherapy. Peripheral blood, measured albumin, prealbumin, globulin, neutrophil count, lymphocyte count, monocyte count, platelet count, hemoglobin, fibrinogen, cancer antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA) were obtained within 1 week of treatment initiation. The reference ranges for plasma albumin, prealbumin, globulin, hemoglobin, and fibrinogen were 35-50 g/L, 160-450 mg/L, 20-35 g/L, 115-155 g/L, and 2-4 g/L, respectively.
The numbers of neutrophils, lymphocytes, monocytes, and platelets were (1.8-6.3) × 10 9 /L, (1.1-3.2) × 10 9 /L, (0.1-0.6) × 10 9 /L, and (100-300) × 10 9 /L, respectively. The accepted normal ranges of CA19-9 and CEA were 0-37 U/mL and 0-5 ng/mL, respectively. The AGR, FAR, PGR, FPR, LMR, NLR, and PLR were defined as albumin (g/L)/globulin (g/L), fibrinogen (g/L)/albumin (g/L) × 100, prealbumin (mg/L)/globulin (g/L), fibrinogen (g/L)/prealbumin (mg/L) × 1000, lymphocytes (10 9 /L)/monocytes (10 9 /L), neutrophils (10 9 /L)/lymphocytes (10 9 /L), and platelets (10 9 /L)/lymphocytes (10 9 /L), respectively. 
| Data analysis methods
| RE SULTS
| Identification of the optimal cutoff value for the seven potential prognostic factors
The ROC curve was used to determine the cutoff values of the seven factors. The seven factors were used as the test variables, and the median PFS time of 200 days was the state variable. The results showed that the optimal cutoff values of AGR, FAR, PGR, FPR, LMR, NLR, and PLR were 1.397 (area under the curve [AUC] = 0.913, P < 0.001), 10.631 (AUC = 0.804, P < 0.001), 5.444 (AUC = 0.844, P < 0.001), 18.490 (AUC = 0.811, P < 0.001), 2.617 (AUC = 0.630, P = 0.059), 4.719 (AUC = 0.598, P = 0.157), and 200.833 (AUC = 0.591, P = 0.186), respectively. Although the AUC of FPR was slightly larger than that of FAR, the AUC of AGR was larger than that of PGR. These mixed results did not show that PGR and FPR were better than AGR and FAR for predicting the prognosis of patients. However, because the AUC value of AGR was 0.913, which is the largest of the four indicators, its prognostic value for PFS in mCRC patients may be superior to the other three indicators ( Figure 1 ).
As the AUCs of the three potential prognostic factors, NLR, LMR, and PLR, were smaller and P > 0.05, these three indicators were excluded, and AGR, FAR, PGR, and FPR were used in the following study. The cutoff values of AGR, FAR, PGR, and FPR were set to 1.40, 10.63, 5.44, and 18.49, respectively. F I G U R E 1 Receiver operating characteristic curve analysis of the albumin-to-globulin ratio (AGR), the lymphocyte-to-monocyte ratio (LMR), and the prealbumin-to-globulin ratio (PGR) (A), and the neutrophil-to-lymphocyte ratio (NLR), the fibrinogen-to-albumin ratio (FAR), the platelet-to-lymphocyte ratio (PLR), and the fibrinogen-to-prealbumin ratio (FPR) (B) in patients with metastatic colorectal cancer According to the RECIST 1.1 criteria, patients with PR and SD accounted for 39.44% and 52.11% of all patients, respectively (Table 1 ).
| Patient characteristics
| Relationship between the four pretreatment prognostic factors and the first-line chemotherapy response
The relationship between the levels of the four prognostic factors before chemotherapy and the treatment response rates was evaluated.
The prechemotherapy levels of AGR, PGR, and FPR in the 71 patients had significant effects on PR, SD, and PD. Although there was a higher proportion of patients in the PR and SD groups from the low FAR (≤10.63) subgroup, this relationship did not achieve statistical significance (P > 0.05; Table 2 ).
Patients in the high AGR (>1.4) and PGR (>5. 44 
| Relationship between four pretreatment prognostic factors and progression-free survival
The median follow-up was 200 days. Thirty-two of the 71 patients (50.7%) experienced tumor progression during follow-up. The median PFS values for the low AGR and high AGR groups were 131 and 236 days (P = 0.002), respectively. The median PFS values for the low FAR and high FAR groups were 208 and 130 days (P = 0.012),
respectively. The median PFS values for the low PGR and high PGR groups were 138 and 221 days (P < 0.001), respectively. The median PFS values for the low FPR and high FPR groups were 214 and 158 days (P = 0.015), respectively. The results showed that the low AGR and PGR groups had lower PFS rates than the high AGR and PGR groups. The high FAR and FPR groups had lower PFS rates than the low FAR and FPR groups ( Figure 2 ).
Univariate Cox regression analyses showed that the risk of disease progression was lower in the low FAR and FPR groups and the high AGR and PGR groups. Moreover, the univariate analysis showed that PFS was significantly related to CA19-9, hemoglobin, histological type, metachronous cancer, peritoneal dissemination, and the number of organs affected by metastasis. After adjusting for the effects of these parameters in the multivariate analysis, pretreatment CA19-9, hemoglobin, and histological type were independent predictors for PFS, which was consistent with the findings of previous research [19] [20] [21] [22] [23] [24] (Table 4 ).
Pearson's correlation analysis implied that the AGR and PGR were positively correlated with PFS in patients with mCRC (Spearman's r = 0.847 and 0.671, respectively; P < 0.001). The FAR and FPR were inversely correlated with PFS in mCRC patients (Spearman's r = −0.561 and −0.576, respectively; P < 0.001; Figure 3 ).
| Correlation between clinicopathological factors and the four prognostic factors
The analysis indicated that a high AGR was closely related to CA19-9 ≤ 37 U/mL, hemoglobin ≥ 115 g/L, well and moderate histological types, and metachronous cancer. High PGR was associated with age <60 years, CA19-9 ≤ 37 U/mL, and hemoglobin ≥ 115 g/L. A correlation was observed between low FAR and only one organ affected by metastasis and hemoglobin ≥ 115 g/L.
Correlations were detected between low FPR and only one organ affected by metastasis, CA19-9 ≤ 37 U/mL, CEA ≤ 5 ng/mL, and hemoglobin ≥ 115 g/L. Interestingly, we found that patients with left-sided colorectal cancer (LSCC) were more likely to have high
AGRs and PGRs and low FARs and FPRs, while patients with rightsided colon cancer (RSCC) were more likely to have low AGRs and high FPRs, although these results were not significant (P > 0.05; Tables 5 and 6 ).
| Subgroup analysis
To investigate whether molecular-targeted drugs can prolong PFS in patients in the high and low subgroups, we analyzed the prognostic significance of targeted therapy stratified by the pretreatment values of the four prognostic factors for mCRC. As a result, the high AGR,
low FAR, and low FPR groups and the use of molecular-targeted therapy tended to prolong patient PFS, while molecular-targeted therapy had no clinical benefit in the low AGR, high FAR, and high FPR groups.
However, this result was not statistically significant (P > 0.05; Table 7 ).
| D ISCUSS I ON
Several recent studies have suggested that the pretreatment AGR, FPR, PLR, NLR, and LMR predict chemotherapeutic outcomes in patients with CRC. [11] [12] [13] [14] 18 However, studies that have considered Since the AUC value of AGR was larger than the other 3 markers, AGR may be more valuable for predicting the PFS of mCRC patients than the other 3 markers.
Nutrition and inflammatory status play a pivotal role in the development of CRC. Poor nutritional status and physical condition are proportional to the levels of inflammation in patients. 25 The The albumin level can reflect the nutritional status of cancer patients. 27 Albumin is an important endogenous antioxidant that can help facilitate the transport of substances and maintain osmotic pressure in the blood vessels. Hypoproteinemia may be associated with cancer, which inhibits the synthesis of albumin by the liver and allows it to reside in pleural and peritoneal effusions. 28 Globulin is a major protein produced by immune organs that reflects the inflammatory and immune status of the human body. 31 Globulin includes not only C-reactive protein but also a variety of acute-phase proteins, such as C3 and serum amyloid A. In chronic inflammation, the level of globulin gradually increases, which reflects the inflammatory state of the body. 32 Studies have shown that the prognosis of cancer patients is closely related to the level of C-reactive protein. 33 Fibrinogen is synthesized by the liver. When the human body is injured, infected, or inflamed, fibrinogen is converted into fibrin. 34 A hypercoagulable state was found in 50% of cancer patients, suggesting a close association between this state and the progression of cancer. 35 The promotion of inflammation, tumor angiogenesis, cell proliferation, aggregation, and metastasis are the main reasons why fibrinogen promotes the development of cancer. 36, 37 The prognosis of cancer patients could be assessed by the level of fibrinogen. 38 Albumin, globulin, and fibrinogen can also be used to indi- with those of previous studies. 39, 40 Prealbumin, as an indicator of malnutrition, has a lower plasma concentration and a 2-day half-life. Although both prealbumin and albumin are negative acute-phase reactants, and prealbumin has the following advantages compared with albumin. First, although albumin is a malnutrition indicator, it is a late indicator, and patients need to be treated with nutritional intervention for approximately 3 weeks before albumin levels increase. However, the prealbumin level will change after 2-3 days of nutritional treatment, as it is a sensitive biomarker for monitoring the timely nutritional and inflammatory status in cancer patients. Second, any change in blood volume can lead to false albumin results.
Some diseases, such as liver disease, bowel disease, kidney disease, lupus, and other diseases that increase capillary permeability, can confound the albumin test results. However, prealbumin results are not easily affected by physiological or pathological factors and provide more current information. In the end, albumin and prealbumin have been used as biomarkers to indicate the long-or short-term nutritional and inflammatory status in cancer patients, respectively. 15, 16 Based on these advantages of prealbumin, in this study, we determined whether PGR and FPR have greater advantages as prognostic factors than AGR and FAR.
When the cutoff value of the predictors was determined by the ROC curve, the AUC of FPR was slightly larger than that of FAR, and the AUC of AGR was larger than that of PGR. The association F I G U R E 3 Pearson's correlation analysis for the linear relationship between the albumin-to-globulin ratio (AGR) (A), the fibrinogen-toalbumin ratio (FAR) (B), the prealbumin-to-globulin ratio (PGR) (C), and the fibrinogen-to-prealbumin ratio (FPR) (D), and progression-free survival (PFS)
between the predictors and the chemotherapy response suggests that FPR may be superior to FAR for predicting the DCR.
Based on these mixed results, we found that only AGR may be superior to the other 3 markers regarding its prognostic value in mCRC patients because its AUC value was the largest. The results showed that PGR and FPR are more accurate prognostic factors for mCRC than AGR, and FAR could not be obtained.
This may be because there is a large amount of time between the earliest tumor stages and the later stages of mCRC, leaving patients in a state of chronic malnutrition and inflammation for a long period. Therefore, prealbumin with a shorter half-life as a prognostic factor did not show a benefit over albumin. Based on this analysis, we speculate that PGR and FPR are superior to AGR and FAR as prognostic factors in patients with early cancer or in Cetuximab and bevacizumab are two molecular-targeted drugs widely used in patients with CRC. The pharmacokinetic characteristics of cetuximab and bevacizumab increase the clearance rates of these two drugs to 20% in patients with low albumin. 46, 47 Exposure to lower therapeutic levels of cetuximab and bevacizumab could adversely impact the molecular-targeted therapeutic response. Therefore, we analyzed the therapeutic effect of targeted therapy on patients with a poor mCRC prognosis. As a result, the two molecular-targeted drugs prolonged PFS in patients with a better prognosis (high AGR and low FAR and FPR subgroups), while these two targeted drugs did not seem to have a therapeutic effect in patients with a poor prognosis (low AGR and high FAR and FPR subgroups). Although the results were not statistically significant because of the small sample size, the same results were reported by a pancreatic cancer study. 48 More similar studies are needed in the future.
Several strengths of this study should be mentioned. First, this is the first report to conceive of PGR as a prognostic factor, specifically, as a prognostic factor for chemotherapeutic response. Second, the results of this study suggest that the AGR may be superior to the FAR, PGR, and FPR in terms of prognostic value in mCRC patients.
Third, the pretreatment AGR, FAR, PGR, and FPR may be correlated with RSCC and LSCC and prognosis. Fourth, there may be some relationship between the pretreatment AGR, FAR, PGR, and FPR and the effect of targeted therapy in mCRC patients. Fifth, these four clinical prognostic indicators are inexpensive, easy to obtain, less invasive, and easily accepted by patients.
This study also had some limitations. First, this study was a single-center retrospective study in which selective bias may arise.
Second, this study was different from other studies in that the NLR, LMR, and PLR were not used as prognostic factors. Moreover, the cutoff values of the AGR, FAR, and FPR were inconsistent with those in previous studies, which may have been caused by the small sample size or the different types of tumors. Third, the AGR, FAR, PGR, and FPR were not independent predictors for PFS in the multivariate analysis, suggesting that these four predictors are susceptible to multiple factors. 29 However, as mentioned above, the AGR, FAR, PGR, and FPR reflect two states of inflammation and nutrition compared with albumin, globulin, fibrinogen, and prealbumin alone, making them more powerful prognostic predictors. Fourth, the follow-up time was relatively short, and the patient's overall survival time was not obtained.
| CON CLUS IONS
The pretreatment AGR, FAR, PGR, and FPR had significant prognostic value for patients with mCRC who received first-line chemotherapy. 
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I N FO R M E D CO N S E NT
Informed consent was obtained from all participants included in the study.
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